GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Proteome Sciences PRM.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

1.45p

+5.07%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in GBP, from our data supplier.

FY2025

Revenue

£3.8m

FY2016FY2025

Net income

−£3.1m

FY2016FY2025

Free cash flow

−£143,000

FY2016FY2025

Shareholders' equity

−£9.5m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue£3.8m£4.9m£5.0m£7.8m£5.1m£4.7m£4.6m£3.0m£3.4m£2.7m
Gross profit−£1.0m−£167,000£1.2m£4.8m£3.0m£2.5m£2.9m£1.9m£2.2m£1.5m
Research and development—£606,000£637,000£376,000£287,000£202,000£355,000£441,000£441,000£1.1m
Operating income−£2.7m−£2.4m−£1.6m£1.5m£512,000£526,000£279,000−£1.4m−£1.8m−£2.7m
Net income−£3.1m−£3.4m−£2.4m£1.3m£72,000£295,000£149,000−£1.3m−£2.5m−£2.3m
Diluted earnings per share-0.01-0.01-0.010.000.000.000.00-0.00-0.01-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets£8.3m£9.2m£11.5m£1.51trn£1.38trn£1.35trn£1.14trn£1.13trn£1.13trn£1.21trn
Cash and short-term investments£781,000£1.1m£2.0m£252.89bn£240.31bn£193.69bn£153.39bn£180.03bn£175.34bn£106.95bn
Total liabilities£17.8m£15.7m£14.5m£1.44trn£1.31trn£1.28trn£1.07trn£1.07trn£1.07trn£119.08bn
Debt£15.8m£14.5m£13.5m£139.92bn£138.58bn£120.95bn£128.01bn£127.18bn£114.29bn£119.08bn
Shareholders' equity−£9.5m−£6.5m−£3.1m£68.29bn£69.05bn£65.80bn£64.43bn£62.56bn£63.91bn£64.87bn
Shares outstanding295m298m295m312m309m295m295m295m296m245m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−£46,000−£826,000−£481,000£2.1m£793,000£1.6m−£21.45bn−£14.78bn£55.47bn−£31.70bn
Capital spending−£97,000−£224,000−£237,000−£1.75bn−£1.72bn−£1.32bn−£1.79bn−£1.40bn−£1.46bn−£1.71bn
Free cash flow−£143,000−£1.1m−£718,000−£1.74bn−£1.72bn−£1.32bn−£23.24bn−£16.18bn£54.02bn−£33.40bn
Dividends paid——−£2.19bn−£1.93bn−£1.36bn−£936.0m————

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
Revenue£1.9m£1.9m£1.9m£2.7m£2.2m£1.8m£3.2m£4.5m
Gross profit−£39,000−£917,000−£89,999£57,999−£225,000−£120,000£1.8m£3.0m
Operating income−£1.2m−£1.0m−£1.6m−£647,000−£1.7m−£1.5m−£163,000£1.5m
Net income−£1.4m−£921,000−£2.1m−£1.2m−£2.2m−£1.9m−£578,000£1.3m
Diluted earnings per share-0.00-0.00-0.01-0.00-0.01-0.01-0.000.00
Cash from operations——————£14.99bn−£9.13bn
Capital spending—————−£1.72bn—−£1.75bn
Free cash flow———————−£10.88bn
Total assets£7.7m£8.3m£8.3m£9.2m£9.5m£11.5m£11.1m£12.4m
Cash and short-term investments£1.1m£781,000£263,000£1.1m£1.2m£2.0m£3.8m£4.0m
Debt£15.5m£14.9m£14.5m£13.5m£12.5m£11.8m£11.1m£11.6m
Shareholders' equity−£9.9m−£9.5m−£8.6m−£6.5m−£5.3m−£3.1m−£1.4m−£843,000

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-21.6%-4.4%7.2%
Operating income——-1.5%
Net income——1.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-13.6%22.2%32.8%42.4%
Operating margin-58.1%-24.0%-13.1%-27.2%
Net margin-74.8%-35.4%-23.1%-33.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-1.4-1.0-1.81.745.78.112.1-1.1-0.8-1.2
Price to sales1.20.70.90.30.60.50.40.50.61.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.